NasdaqCM:PAVM

Stock Analysis Report

Executive Summary

PAVmed Inc. operates as a medical device company in the United States.

Snowflake

Fundamentals

Worrying balance sheet with weak fundamentals.

Risks

  • PAVmed has significant price volatility in the past 3 months.
  • PAVmed is covered by less than 3 analysts.

Share Price & News

How has PAVmed's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-3.9%

NasdaqCM:PAVM

1.5%

US Medical Equipment

0.8%

US Market


1 Year Return

-23.2%

NasdaqCM:PAVM

9.7%

US Medical Equipment

1.9%

US Market

PAVM underperformed the Medical Equipment industry which returned 9.6% over the past year.

PAVM underperformed the Market in United States of America which returned 2.1% over the past year.


Share holder returns

PAVMIndustryMarket
7 Day-3.9%1.5%0.8%
30 Day-4.8%0.7%3.4%
90 Day-17.9%2.4%2.1%
1 Year-23.2%-23.2%10.6%9.7%4.2%1.9%
3 Year-93.2%-93.2%70.2%65.0%46.7%37.2%
5 Yearn/a136.0%109.1%62.3%44.5%

Price Volatility Vs. Market

How volatile is PAVmed's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is PAVmed undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether PAVmed is trading at an attractive price based on the cash flow it is expected to produce in the future. But as PAVmed has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is PAVmed expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

47.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if PAVmed is high growth as no revenue estimate data is available.

PAVmed is not considered high growth as it is expected to be loss making for the next 1-3 years.

Unable to compare PAVmed's revenue growth to the United States of America market average as no estimate data is available.

Unable to compare PAVmed's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare PAVmed's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if PAVmed will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has PAVmed performed over the past 5 years?

-47.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

PAVmed does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare PAVmed's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare PAVmed's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if PAVmed has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if PAVmed has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if PAVmed improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.


Next Steps

Financial Health

How is PAVmed's financial position?


Financial Position Analysis

PAVmed's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

PAVmed has no long term commitments.


Debt to Equity History and Analysis

PAVmed has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if PAVmed's debt level has increased considering it has negative shareholder equity.


Balance Sheet

Low level of unsold assets.

PAVmed has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

PAVmed has less than a year of cash runway based on current free cash flow.

PAVmed has less than a year of cash runway if free cash flow continues to grow at historical rates of 36.1% each year.


Next Steps

Dividend

What is PAVmed's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate PAVmed's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate PAVmed's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as PAVmed has not reported any payouts.

Unable to verify if PAVmed's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as PAVmed has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of PAVmed's salary, the management and board of directors tenure and is there insider trading?

3.0yrs

Average management tenure


CEO

Lishan Aklog (53yo)

5.3yrs

Tenure

US$772,393

Compensation

Dr. Lishan Aklog, M.D, serves as the Chairman and Chief Executive Officer at PAVmed Inc. since June 26, 2014. He serves an Advisor at WI Harper Group. Dr. Aklog is a Founder and Principal of Pavilion Holdi ...


CEO Compensation Analysis

Lishan's remuneration is higher than average for companies of similar size in United States of America.

Lishan's compensation has increased whilst company is loss making.


Management Age and Tenure

3.0yrs

Average Tenure

54yo

Average Age

The tenure for the PAVmed management team is about average.


Board Age and Tenure

4.8yrs

Average Tenure

62yo

Average Age

The tenure for the PAVmed board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$5,42928 May 19
Dennis McGrath
EntityIndividual
Role
President
President
Shares5,000
Max PriceUS$1.09
BuyUS$32,85028 May 19
Lishan Aklog
EntityIndividual
Role
Chief Executive Officer
Chairman & CEO
Shares30,000
Max PriceUS$1.10

Ownership Breakdown


Management Team

  • Dennis McGrath (62yo)

    President

    • Tenure: 0.5yrs
    • Compensation: US$697.64k
  • Lishan Aklog (53yo)

    Chairman & CEO

    • Tenure: 5.3yrs
    • Compensation: US$772.39k
  • Brian deGuzman (54yo)

    Chief Medical Officer

    • Tenure: 4.9yrs
    • Compensation: US$484.15k
  • Shaun O'Neil

    Chief Commercial Officer

    • Tenure: 1.2yrs
  • Mike Havrilla

    Director of Investor Relations

    • Tenure: 0yrs

Board Members

  • Ron Sparks (64yo)

    Director

    • Tenure: 4.7yrs
    • Compensation: US$128.82k
  • David Weild (62yo)

    Director

    • Tenure: 4.6yrs
    • Compensation: US$141.53k
  • Todd Rosengart

    Member of Medical Advisory Board

    • Tenure: 4.8yrs
  • James Cox (75yo)

    Director

    • Tenure: 4.7yrs
    • Compensation: US$122.15k
  • Marc Gerdisch

    Member of Medical Advisory Board

    • Tenure: 4.8yrs
  • Lishan Aklog (53yo)

    Chairman & CEO

    • Tenure: 5.3yrs
    • Compensation: US$772.39k
  • Philip Stieg

    Member of Medical Advisory Board

    • Tenure: 4.7yrs
  • Al Chin

    Member of Medical Advisory Board

    • Tenure: 4.7yrs
  • Mike Glennon (53yo)

    Vice Chairman

    • Tenure: 4.9yrs
    • Compensation: US$69.65k
  • Timothy Murphy

    Member of Medical Advisory Board

    • Tenure: 4.8yrs

Company Information

PAVmed Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PAVmed Inc.
  • Ticker: PAVM
  • Exchange: NasdaqCM
  • Founded: 2014
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$33.382m
  • Shares outstanding: 35.06m
  • Website: https://www.pavmed.com

Number of Employees


Location

  • PAVmed Inc.
  • One Grand Central Place
  • Suite 4600
  • New York
  • New York
  • 10165
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PAVMNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJul 2016
1P5BST (Boerse-Stuttgart)YesCommon StockDEEURJul 2016

Biography

PAVmed Inc. operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive c ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/18 01:19
End of Day Share Price2019/09/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.